Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder .

http://www.news-medical.net/news/20130426/Neuralstem-gets-approval-from-FDA-for-dosing-cohort-patients-in-NSI-189-Phase-Ib-in-MDD-treatment.aspx